AMLX
No price yet
Announcements
Nothing here yet
Daily updates
FDA designations
Nothing here yet
News
- Amylyx Pharmaceuticals reported positive topline results from the Phase 3 LUCIDITY trial of avexitide in post-bariatric hypoglycemiaAug 18, 2026
- Amylyx Pharmaceuticals completed enrollment in the Phase 3 LUCIDITY trial of Avexitide for post-bariatric hypoglycemiaMar 24, 2026
- Amylyx Pharmaceuticals nominated AMX0318 as GLP-1 receptor antagonist candidateJan 8, 2026
- Amylyx Pharmaceuticals to discontinue ORION program of AMX0035 for progressive supranuclear palsy (PSP)Aug 27, 2025
- Amylyx Pharmaceuticals presents new exploratory analyses from Phase 2 and 2b trials of Avexitide in post-bariatric hypoglycemia at ENDO 2025Jul 14, 2025